Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,

#4369 The predictive value of 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG PET/CT in patients with paragangliomas

Introduction: Paragangliomas (PGLs) are rare neuroendocrine tumours with variable clinical outcomes. Early identification of prognostic markers is essential for effective disease management. PET/CT imaging with 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG offers unique insights into tumour biology, respectively.

Conference:

Presenting Author: Xu J

Authors: Gao J, Xu J, Liang Y, Chen J, Song S,

Keywords: PET/CT, paraganglioma, prognosis,

#3985 Comparison of the diagnostic value of 68Ga-DOTANOC, 18F-FDOPA, and18F-FDG PET/CT for metastatic paraganglioma

Introduction: Functional imaging is important for precise treatment for metastatic paraganglioma (PGL).

Conference:

Presenting Author: Xu J

Authors: Bian L, Xu J, Xu X, Chen J, Song S,

Keywords: paraganglioma, 18F-FDG, 68Ga-DOTANOC, 18F-DOPA, PET/CT,

#3277 Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms

Introduction: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor affinity with 68Ga-DOTA, is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). 18F-FDOPA tracer is also used in the diagnostic imaging of NENs, likely detecting additional lesions compared to 68Ga-DOTA.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Veenstra E, Noordzij W,

Keywords: neuroendocrine tumor, PET tracer, 18F-DOPA, 68Ga-DOTA-TOC, carbidopa, peptide receptor radionuclide therapy, PRRT,